Last Updated: 02/16/18
- Tumor Target
Status: Phase 0 - NF2 Pre-Clinical
Tumor Target: Vestibular Schwannoma (VS)
Class: Progesterone Receptor Antagonist
Massachusetts Eye and Ear researchers have shown that Mifepristone (RU-482), a drug currently FDA-approved for chemical abortion,
can also prevent the growth of vestibular schwannoma.
"Adverse effects for mifepristone include mild fatigue, hot flashes, nausea and rash. Long-term use of mifepristone has been studied
in clinical trials for other tumors, with minimal adverse effects reported after years of usage.
"Side Effects; nausea, vomiting, diarrhea, weakness, or dizziness may occur. Serious side effects; fever of 100.4 degrees F
(38 degrees C) or higher, fainting, fast heartbeat, stomach/abdominal pain or tenderness."
- Massachusetts Eye and Ear. "Mifepristone may halt growth of intracranial tumor that causes hearing loss." (2018)
- Nature. "Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma."(2018)
- FDA. "Mifeprex (mifepristone) Information" (2018)
- ScienceDaily. "Mifepristone may halt growth of intracranial tumor that causes hearing loss." (2018)
- WebMD. "Mifepristone Tablet" (2018)
- ChemSpider. "Mifepristone."